A Look At Moderna’s Pipeline Beyond The COVID Vaccine
- Tuesday, May 26, 2020, 7:12
- Market
- Add a comment
Moderna stock is up by about 270% year-to-date, driven largely by the positive news surrounding the company’s COVID-19 vaccine, which is moving to phase 2 clinical trials. The company’s market cap has risen from roughly $7 billion earlier this year to close to $27 billion currently…
About the Author
admin123 has written 23527 stories on this site.
